Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis

British Journal of Cancer

Volumn 95, Issue 11, 2006, Pages 1467-1473

  Aapro, M ^a   Coiffier, B ^b   Dunst, J ^c   Osterborg A ^d   Burger, H U ^e  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Anaemia; Epoetin beta; Survival

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFECT; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DISEASE PROGRESSION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE;

EID: 33845334505     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603481     Document Type: Article

References (34)

1. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A (2003) Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162: 1789-1806
2. Antonadou D, Cardamakis E, Puglisi M (2001) Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies: final results of a randomized phase III study. Eur J Cancer 37(Suppl 6): A530
3. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, Engert A (2004) Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 3: CD003407
4. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97: 489-498
5. Bohlius J, Wilson J, Seidenfeld S, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett C, Langensiepen S, Hyde C, Engert A (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98: 708-714
6. Boogaerts M, Coiffier B, Kainz C, Epoetin Beta QOL, Working Group (2003) Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 88: 988-995
7. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91: 2214-2221
8. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122: 386-393
9. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegier L, Essers U, Greil R, Grossi A, Jager G, Le Mevel A, Najman A, Silingardi V, Spriano M, Van Hoof A, Ehmer B (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86: 4446-4453
10. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25(Suppl 7): 43-46
11. Dunst J (2004) Erythropoietin and radiotherapy: a dangerous combination? Strahlenther Onkol 180: 133-135
12. Farrell F, Lee A (2004) The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9(Suppl 5): 18-30
13. Food and Drug Administration (2004) Oncologic Drugs Advisory Committee. Meeting on evolving safety issues associated with erythropoietic products. Briefing information. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037b2.htm (4 May 2004)
14. Glaser CM, Millesi W, Kornek GV, Long S, Schull B, Watzinger F, Selzer E, Lavey RS (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50: 705-715
15. Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amade RG (2005) Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 23: 6941-6948
16. Henke M, Laszig R, Rube C, Schafer U, Hasse KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260
17. Kettelhack C, Hones C, Messinger D, Schlag PM (1998) Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg 85: 63-67
18. Lee AY, Levine MN (2003) Venous thromboembolism and cancer: risks and outcomes. Circulation 107(23 Suppl 1): I17-I21
19. Leyland-Jones B, Mahmud S (2004) Erythropoietin to treat anaemia in patients with head and neck cancer [letter]. Lancet 363: 80
20. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandi S, Makhson A, Roth A, Dodwell D, Basalga J, Biakhov M, Valuckas K, Voznui E, Lui X, Vercammen E (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960-5972
21. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapaport B, Epoetin Alpha study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865-2874
22. Mittelman M, Neumann D, Peled A, Kanter P, Haren-Ghera N (2001) Erythropoietin induces tumour regression and antitumour immune responses in murine myeloma models. Proc Natl Acad Sci USA 98: 5181-5186
23. Möbus VJ, Untch M, Du Bois A, Lueck H-J, Thomssen C, Kuhn W, Kurbacher C, Nitz U, Kreienberg R, Jackisch C (2004) Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥4+LN). First results of an AGO-trial. J Clin Oncol 22: 14S Abstract 513
24. NeoRecormon® SmPC (2006) Available from: www.rocheuk.com/ProductDB/ Documents/rx/spc/NeoRecormon_PFS_SPC.pdf 27 September 2006)
25. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrman R, Netter-Pinon J, Tubiana-Mathiew N, Zwierzina H (1998) Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 9: 255-260
26. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkdyrov K, Hedenus M, Messinger D, Epoetin Beta Hematology Study Group (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20: 2486-2494
27. Österborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najmen A, Peest D (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood 87: 2675-2682
28. Österborg A, Brandberg Y, Hedenus M (2005) Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 129: 206-209
29. Rau B, Schlag PM, Willeke F, Herforth C, Stephen P, Frake W (1998) Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO). Eur J Cancer 34: 992-998
30. Stuben G, Pottgen C, Knuhmann K, Schmidt K, Stusche M, Thews O, Vaupel P (2003) Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phy 55: 1358-1362
31. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Haeven JJ, Reeds NS, Fairlamb DJ, Chan SY, Godfrey KA Kristenson GB, van Tinteren H, Ehmer B (1998) Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15: 174-182
32. Thews O, Kelleher DK, Vaupel P (2001) Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 61: 1358-1361
33. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gatekey J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211-1220
34. Vaupel P, Mayer A (2004) Erythropoietin to treat anaemia in patients with head and neck cancer [letter]. Lancet 363: 992